Opus Genetics, Inc. (IRD) - Net Assets
Based on the latest financial reports, Opus Genetics, Inc. (IRD) has net assets worth $15.35 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($50.24 Million) and total liabilities ($34.90 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Opus Genetics, Inc. asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $15.35 Million |
| % of Total Assets | 30.55% |
| Annual Growth Rate | N/A |
| 5-Year Change | -30.93% |
| 10-Year Change | N/A |
| Growth Volatility | 85.82 |
Opus Genetics, Inc. - Net Assets Trend (2019–2025)
This chart illustrates how Opus Genetics, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore IRD current and non-current assets for the complete picture of this company's asset base.
Annual Net Assets for Opus Genetics, Inc. (2019–2025)
The table below shows the annual net assets of Opus Genetics, Inc. from 2019 to 2025. For live valuation and market cap data, see Opus Genetics, Inc. (IRD) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $15.35 Million | +128.26% |
| 2024-12-31 | $6.72 Million | -86.53% |
| 2023-12-31 | $49.91 Million | +7.93% |
| 2022-12-31 | $46.24 Million | +108.08% |
| 2021-12-31 | $22.22 Million | +265.01% |
| 2020-12-31 | $-13.47 Million | -78.13% |
| 2019-12-31 | $-7.56 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Opus Genetics, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 18053400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.05% |
| Other Components | $203.93 Million | 1328.71% |
| Total Equity | $15.35 Million | 100.00% |
Opus Genetics, Inc. Competitors by Market Cap
The table below lists competitors of Opus Genetics, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hyundai Green Food Co. Ltd.
KO:453340
|
$365.74 Million |
|
Haibo Heavy Engineering Science and Technology Co Ltd
SHE:300517
|
$366.00 Million |
|
Meter Instruments Co. Ltd
SHE:301006
|
$366.04 Million |
|
Sichuan Huati Lighting Tech
SHG:603679
|
$366.10 Million |
|
Shanxi Tond Chemical Co Ltd
SHE:002360
|
$365.69 Million |
|
Palram
TA:PLRM
|
$365.54 Million |
|
ATN International Inc
NASDAQ:ATNI
|
$365.41 Million |
|
Agro Tech Foods Limited
NSE:ATFL
|
$365.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Opus Genetics, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 6,724,000 to 15,348,000, a change of 8,624,000 (128.3%).
- Net loss of 49,591,000 reduced equity.
- Share repurchases of 152,000 reduced equity.
- New share issuances of 34,784,000 increased equity.
- Other factors increased equity by 23,583,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-49.59 Million | -323.11% |
| Share Repurchases | $152.00K | -0.99% |
| Share Issuances | $34.78 Million | +226.64% |
| Other Changes | $23.58 Million | +153.66% |
| Total Change | $- | 128.26% |
Book Value vs Market Value Analysis
This analysis compares Opus Genetics, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 208.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-1.07 | $5.14 | x |
| 2020-12-31 | $-2.89 | $5.14 | x |
| 2021-12-31 | $1.50 | $5.14 | x |
| 2022-12-31 | $2.24 | $5.14 | x |
| 2023-12-31 | $2.31 | $5.14 | x |
| 2024-12-31 | $0.25 | $5.14 | x |
| 2025-12-31 | $0.02 | $5.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Opus Genetics, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -323.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -349.33%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 3.27x
- Recent ROE (-323.11%) is below the historical average (-202.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.41 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.27 Million |
| 2021 | -255.12% | -9625.30% | 0.02x | 1.17x | $-58.92 Million |
| 2022 | 38.69% | 44.89% | 0.81x | 1.06x | $13.26 Million |
| 2023 | -20.01% | -52.42% | 0.35x | 1.08x | $-14.98 Million |
| 2024 | -855.62% | -523.40% | 0.30x | 5.48x | $-58.20 Million |
| 2025 | -323.11% | -349.33% | 0.28x | 3.27x | $-51.13 Million |
Industry Comparison
This section compares Opus Genetics, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $15.35 Million | 0.00% | 2.27x | $365.71 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 t… Read more